AZD-5991

Name: AZD-5991
Brand: MedChemExpress
SKU: HY-101533
Rating: 5.0 (19 reviews)

製品番号: HY-101533 純度: 99.79%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC₅₀ of 0.7 nM in FRET assay and a K_d of 0.17 nM in surface plasmon resonance (SPR) assay.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 2143061-81-6

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 518	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 518	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$350	在庫あり	Estimated Time of Arrival: December 31
10 mg	$550	在庫あり	Estimated Time of Arrival: December 31
25 mg	$980	在庫あり	Estimated Time of Arrival: December 31
50 mg	$1375	在庫あり	Estimated Time of Arrival: December 31
100 mg	$1835	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 19 publication(s) in Google Scholar

Other Forms of AZD-5991:

AZD-5991 (S-enantiomer) 在庫あり
AZD-5991 Racemate お問い合わせ
AZD-5991 (Standard) お問い合わせ

顧客検証

Cell Proliferation/Viability Assay

Cell Imaging/Staining

: AZD-5991 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 21;16(1):7689. [Abstract]; CDS tumoroids were highly sensitive to AZD-5991 (0.0001-10 μM).

: AZD-5991 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):256. [Abstract]; Cell viability in MMCLs after treatment with AZD-5991 (0.0001-10 μM), with calculated IC₅₀ values.

: AZD-5991 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]; MCL-1 inhibitors AZD-5991 (500 nM) stabilized MCL-1, but repressed the ability of human MCL-1 to co-precipitate with ACSL1 and BIM in 293T cells.

: AZD-5991 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]; MCL-1 inhibitors AZD-5991 (500 nM) significantly repressed the utilization of oleate-containing LDs in Mcl1F/F Rosa-ERCreT2 MEFs reconstituted with human MCL1.

: AZD-5991 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]; MCL-1 inhibitor AZD-5991 (1 mM) disrupted BIM and ACSL1 interactions with MCL-1.

Bcl-2 Family アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC₅₀ of 0.7 nM in FRET assay and a K_d of 0.17 nM in surface plasmon resonance (SPR) assay^[1].

IC₅₀ & Target^[1]

Mcl-1

0.7 nM (IC₅₀)

Mcl-1

0.17 nM (Kd)

Cellular Effect

Cell Line	Type	Value	Description	References
AMO1	EC₅₀	22.9 nM Compound: AZD5991	Antiproliferative activity against human AMO1 cells assessed as reduction in cell viability Antiproliferative activity against human AMO1 cells assessed as reduction in cell viability	[PMID: 38597264]
K562	IC₅₀	29.6 μM Compound: 5; AZD5991	Antiproliferative activity against human K562 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 34342996]
MOLP-8	EC₅₀	33 nM Compound: AZD5991	Antiproliferative activity against human MOLP8 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo reagent based assay Antiproliferative activity against human MOLP8 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo reagent based assay	[PMID: 38597264]
MV4-11	EC₅₀	24 nM Compound: AZD5991	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo reagent based assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo reagent based assay	[PMID: 38597264]
MV4-11	EC₅₀	34.9 nM Compound: AZD5991	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability	[PMID: 38597264]
MV4-11	IC₅₀	0.024 μM Compound: 5; AZD5991	Antiproliferative activity against human MV4-11 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 34342996]
NCI-H23	EC₅₀	190 nM Compound: AZD5991	Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo reagent based assay Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo reagent based assay	[PMID: 38597264]
NCI-H23	IC₅₀	0.19 μM Compound: 5; AZD5991	Antiproliferative activity against human NCI-H23 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H23 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 34342996]
NCI-H929	EC₅₀	31.7 nM Compound: AZD5991	Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability	[PMID: 38597264]
NCI-H929	IC₅₀	0.036 μM Compound: 5; AZD5991	Antiproliferative activity against human NCI-H929 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H929 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 34342996]
SK-BR-3	IC₅₀	30 μM Compound: 5; AZD5991	Antiproliferative activity against human SK-BR-3 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 34342996]

体外実験

The selectivity of AZD-5991 is evaluated against pro-survival Bcl-2 family members using FRET assays. AZD-5991 is selective for Mcl-1 (IC₅₀ 0.72 nM, K_i=200 pM) vs. Bcl-2 (IC₅₀=20 μM, K_i=6.8 μM), Bcl-xL (IC₅₀=36 μM, K_i=18 μM), Bcl-w (IC₅₀=49 μM, K_i=25 μM), and Bfl-1 (IC₅₀=24 μM, K_i=12 μM). MOLP-8, MV4-11, and NCI-H23 cells are treated with AZD5991 (EC₅₀=0.033, 0.024, 0.19 μM, respectively).AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 reduces the levels of Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines further supporting the notion that activation of caspases by AZD5991 reduces Mcl-1 protein levels in AZD5991-sensitive cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

A single intravenous (i.v.) dose of AZD5991 leads to a dose-dependent antitumor effect ranging from tumor growth inhibition (TGI) to tumor regression (TR). Ten days after treatment, AZD5991 shows 52% and 93% TGI (p<0.0001) at 10 and 30 mg/kg, respectively. At the same time point, AZD5991 at 60 mg/kg leads to 99% TR with no detectable tumors in 6 out of 7 mice, while complete TR is seen in 7 out of 7 mice in the 100 mg/kg dose group. AZD5991 also shows a dose-dependent duration of response with tumors in the 100 mg/kg group growing back later than those in the 60 mg/kg group. The magnitude of in vivo tumor efficacy is correlated with activation of caspase-3 in the tumor and concentration of AZD5991 in plasma. Treatment with AZD5991 was well tolerated at all dose levels with no significant body weight loss. A single dose of AZD5991 36 days after the first dose causes tumor regression in 4 out of 4 mice. In mice dosed with AZD5991 at 100 mg/kg on day 0 and day 1, tumors grow back later than those dosed with a single dose of AZD5991 at the same dose level^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

672.26

分子式

C₃₅H₃₄ClN₅O₃S₂

CAS 番号

2143061-81-6

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)C1=C(CCCOC2=C(C=CC=C3)C3=CC4=C2)C5=C(N1C)C(C6=C(C)N(C)N=C6CSCC7=NN(C)C(CS4)=C7)=C(Cl)C=C5

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 250 mg/mL (371.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.4875 mL	7.4376 mL	14.8752 mL
5 mM	0.2975 mL	1.4875 mL	2.9750 mL
10 mM	0.1488 mL	0.7438 mL	1.4875 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.09 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.79%

Select Batch:

データシート (287 KB) SDS (393 KB)

COA (265 KB) LCMS (91 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Tron AE, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018 Dec 17;9(1):5341. [Content Brief]

動物実験
^[1]

Mice and Rats^[1]
In mice, drugs (e.g., AZD5991; 10-100 mg/kg) are dosed intravenously in a volume of 5 mL/kg except for Venetoclax that is dosed orally in a volume of 10 mL/kg. One million MV4-11, five million MOLP-8, ten million NCI-H929 or five million OCI-AML3 cells are injected subcutaneously in the right flank of mice in a volume of 0.1 mL. In rats, AZD5991 (10-100 mg/kg) is dosed intravenously in a volume of 10 mL/kg. Ten million MV4-11 cells are injected subcutaneously in the right flank of rats in a volume of 0.1 mL. Tumor volumes (measured by caliper), animal body weight, and tumor condition are recorded twice weekly for the duration of the study. The tumor volume is calculated^[1].

MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。

参考文献

[1]. Tron AE, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018 Dec 17;9(1):5341. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.4875 mL	7.4376 mL	14.8752 mL	37.1880 mL
	5 mM	0.2975 mL	1.4875 mL	2.9750 mL	7.4376 mL
	10 mM	0.1488 mL	0.7438 mL	1.4875 mL	3.7188 mL
	15 mM	0.0992 mL	0.4958 mL	0.9917 mL	2.4792 mL
	20 mM	0.0744 mL	0.3719 mL	0.7438 mL	1.8594 mL
	25 mM	0.0595 mL	0.2975 mL	0.5950 mL	1.4875 mL
	30 mM	0.0496 mL	0.2479 mL	0.4958 mL	1.2396 mL
	40 mM	0.0372 mL	0.1859 mL	0.3719 mL	0.9297 mL
	50 mM	0.0298 mL	0.1488 mL	0.2975 mL	0.7438 mL
	60 mM	0.0248 mL	0.1240 mL	0.2479 mL	0.6198 mL
	80 mM	0.0186 mL	0.0930 mL	0.1859 mL	0.4648 mL
	100 mM	0.0149 mL	0.0744 mL	0.1488 mL	0.3719 mL

AZD-5991 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AZD-59912143061-81-6AZD5991AZD 5991Bcl-2 FamilyInhibitorinhibitorinhibit

最近チェックした製品:

製品名

カスタマ需要量 *

お名前 *

タイトル

メールアドレス *

電話番号 *

デパートメント

組纖名 *

市区町村

都道府県

国或いは地域 *

必ず会社名を記載ください。個人への返信は行いません。

備考

製品名

Lot #

お名前 *

メールアドレス *

電話番号 *

部門 *

組纖名 *

国或いは地域 *

備考

AZD-5991

カスタマーレビュー

Other Forms of AZD-5991:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Bcl-2 Family アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

AZD-5991 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

AZD-5991

カスタマーレビュー

Other Forms of AZD-5991:

AZD-5991 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Bcl-2 Family アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

AZD-5991 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

AZD-5991 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report